Concomitant use increases CNS depression with additive or supra-additive effects on driving ability, vigilance, alertness, and increased anger, confusion, and depression.
Source: NLP:perampanel
Brand names: Fycompa
Noncompetitive AMPA Glutamate Receptor Antagonist · AMPA Receptor Antagonists · UGT2B7 Inhibitors · UGT1A9 Inhibitors · Cytochrome P450 3A4 Inhibitors · Cytochrome P450 2C8 Inhibitors
Route: Oral
FDA Black Box Warning
WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA ( 5.1 ). These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression ( 5.1 ). Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA ( 5.1 ). Closely monitor patients particularly during the titration period and at higher doses ( 5.1 ). FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening ( 5.1 ). WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS See full prescribing information for complete boxed warning. Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA ( 5.1 ) Monitor patients for these reactions as well as for changes in mood, behavior, or personality that are not typical for the patient, particularly during the titration period and at higher doses ( 5.1 ) FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening ( 5.1 )
Contraindications
4 CONTRAINDICATIONS None. None ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as perampanel, during pregnancy. Encourage women who are taking perampanel during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org. Risk Summary There are no adequate data on the developmental risk associated with use in pregnant women. In animal studies, perampanel induced developmental toxicity in pregnant rat and rabbit at clinically relevant doses [see Data] . In the U.S. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data Oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rats throughout organogenesis resulted in an increase in visceral abnormalities (diverticulum of the intestine) at all doses tested; maternal toxicity was observed at the mid and high doses. In a dose-ranging study at higher oral doses (10, 30, or 60 mg/kg/day), embryo lethality and reduced fetal body weight were observed at the mid and high doses tested. The lowest dose tested (1 mg/kg/day) is similar to a human dose of 8 mg/day based on body surface area (mg/m 2 ). Upon oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rabbits throughout organogenesis, embryo lethality and maternal toxicity were observed at the mid and high doses tested; the no-effect dose for embryo-fetal developmental toxicity in rabbit (1 mg/kg/day) is approximately 2 times a human dose of 8 mg/day based on body surface area (mg/m 2 ). Oral administration of perampanel (1, 3, or 10 mg/kg/day) to rats throughout gestation and lactation resulted in fetal and pup deaths at the mid and h
8 interactions on record
Concomitant use increases CNS depression with additive or supra-additive effects on driving ability, vigilance, alertness, and increased anger, confusion, and depression.
Source: NLP:perampanel
CNS depressants that may increase CNS depression when used with FYCOMPA. Patients should limit activity until experienced with concomitant use.
Source: NLP:perampanel
Decreases perampanel plasma concentrations by approximately 50-67%. Dose adjustment of FYCOMPA may be necessary; monitor closely when introduced or withdrawn.
Source: NLP:perampanel
FYCOMPA 12 mg daily decreases levonorgestrel exposure by approximately 40%, potentially reducing contraceptive effectiveness. Additional non-hormonal contraception is recommended.
Source: NLP:perampanel
CNS depressants that may increase CNS depression when used with FYCOMPA. Patients should limit activity until experienced with concomitant use.
Source: NLP:perampanel
Decreases perampanel plasma concentrations by approximately 50-67%. Dose adjustment of FYCOMPA may be necessary; monitor closely when introduced or withdrawn.
Source: NLP:perampanel
Decreases perampanel plasma concentrations by approximately 50-67%. Dose adjustment of FYCOMPA may be necessary; monitor closely when introduced or withdrawn.
Source: NLP:perampanel
CNS depressants that may increase CNS depression when used with FYCOMPA. Patients should limit activity until experienced with concomitant use.
Source: NLP:perampanel